Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 11/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29680626 | 1.00 | CRBN (0.42) | CRBNMAPKAPK2SIGMAR1HTR2AALDH1A1 | |
| SCHEMBL1207857 | 0.87 | CRBN (0.47) | CRBNMAPKAPK2SIGMAR1HTR2AALDH1A1 | |
| SCHEMBL21238835 | 0.86 | — | — | |
| SCHEMBL1810656 | 0.85 | CRBN (0.50) | CRBNMAPKAPK2SIGMAR1HTR2AALDH1A1 | |
| SCHEMBL30633804 | 0.85 | CRBN (0.50) | CRBNMAPKAPK2SIGMAR1HTR2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2635798 | 0.85 | CRBN (0.46) | CRBNMAPKAPK2SIGMAR1HTR2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2635797 | 0.85 | CRBN (0.46) | CRBNMAPKAPK2SIGMAR1HTR2AALDH1A1 | |
| SCHEMBL549600 | 0.85 | CRBN (0.50) | CRBNMAPKAPK2SIGMAR1HTR2AALDH1A1 | |
| SCHEMBL20758531 | 0.84 | CRBN (0.39) | CRBNOTUD7B | |
| SCHEMBL21225403 | 0.83 | CRBN (0.44) | CRBNALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| WO-2023018810-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | CRBN 1675/4885MAPKAPK2 455/4885SIGMAR1 4638/4885 |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CRBN 1169/4885MAPKAPK2 840/4885SIGMAR1 4282/4885 |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CRBN 1529/4885MAPKAPK2 1477/4885SIGMAR1 4644/4885 |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | CRBN 1604/4885MAPKAPK2 1190/4885SIGMAR1 4401/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | CRBN 1604/4885MAPKAPK2 1190/4885SIGMAR1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.